Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07097311 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
A Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency, sponsored by Jerry Vockley, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07097311: Recruiting Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency, sponsored by Jerry Vockley, MD, PhD.
NCT07097311 is a Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency that is actively recruiting participants, run by Jerry Vockley, MD, PhD. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07097311, a Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency, is actively recruiting participants, sponsored by Jerry Vockley, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of long chain fatty acid oxidation disorders (FAODs). Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin patients with MCADD.
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT07097311 shows while recruiting
NCT07097311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Medium-chain Acyl-CoA Dehydrogenase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT07097311 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07097311 about?
NCT07097311 is a clinical study titled "Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)". This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of long chain fatty acid oxidation disorders (FAO...
What is the current status of trial NCT07097311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-07. Estimated completion is 2028-04.
What conditions does trial NCT07097311 study?
This clinical trial studies the following conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency.
What interventions are being tested in trial NCT07097311?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT07097311?
This trial is sponsored by Jerry Vockley, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07097311 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medium-chain Acyl-CoA Dehydrogenase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07097311's enrollment target sits among peer trials
24 1756th of 2000 higher than 218 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia